Clinical Trials Logo

Primary Liver Carcinoma clinical trials

View clinical trials related to Primary Liver Carcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03397654 Active, not recruiting - Clinical trials for Primary Liver Carcinoma

Study of Pembrolizumab Following TACE in Primary Liver Carcinoma

PETAL
Start date: January 28, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Open label, single arm, multi-centre study of pembrolizumab following trans-arterial chemoembolization (TACE). Twenty-six to 32 evaluable participants with primary liver cancer (hepatocellular cancer; HCC) will be assessed. The primary objective is to determine the safety and tolerability of pembrolizumab following TACE. The secondary objective is to evaluate the efficacy of pembrolizumab following TACE by improving progression-free survival rates as measured by modified response evaluation criteria in solid tumours (mRECIST) criteria.